Upcoming AWS Coverage on PetMed Express Post-Earnings Results

LONDON, UK / ACCESSWIRE / May 2, 2017 / Active Wall St. blog coverage looks at the headline from Alkermes PLC (NASDAQ: ALKS) as the Company announced on May 01, 2017, the completion of patient enrollment in ENLIGHTEN-1, the first of two-key phase-3 studies in the ENLIGHTEN clinical development program for ALKS 3831. The Company's drug is an investigational, novel, once-daily, oral atypical antipsychotic candidate for the treatment of schizophrenia. ALKS 3831 is composed of samidorphan, a novel, new molecular entity co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet. Register with us now for your free membership and blog access at:

http://www.activewallst.com/register/

One of Alkermes's competitors within the Drug Delivery space, PetMed Express, Inc. (NASDAQ: PETS), announced on May 01, 2017, that it will release its financial results for the fiscal year ended March 31, 2017 on Monday, May 08, 2017 at 8:00 A.M. ET, then at 8:30 A.M. ET, Menderes Akdag, the Company's CEO and President, will host a conference call to review the financial results. AWS will be initiating a research report on PetMed Express in the coming days.

Today, AWS is promoting its blog coverage on ALKS; touching on PETS. Get all of our free blog coverage and more by clicking on the link below:

http://www.activewallst.com/register/

ENLIGHTEN Study

The ENLIGHTEN clinical development program for ALKS 3831 comprises of two key studies: firstly, comparing the antipsychotic efficacy of ALKS 3831 to placebo over four weeks and secondly, evaluating weight gain with ALKS 3831 compared to olanzapine in patients with schizophrenia over six months.

Alkermes' multinational, randomized, double-blind phase-3 study is designed to evaluate the antipsychotic efficacy of ALKS 3831 compared to placebo over four weeks in patients experiencing an acute exacerbation of schizophrenia. The study also includes a comparator arm of olanzapine, an established atypical antipsychotic agent with proven efficacy but also metabolic liabilities, including significant weight gain. Top-line results from the study are expected in mid-2017.

Alkermes' ENLIGHTEN-2, is the second key study from the ENLIGHTEN development program for ALKS 3831. The trial is currently ongoing and enrolling patients with data expected mid-2018. The study is designed to evaluate the weight gain profile of ALKS 3831 in patients with schizophrenia over a six-month treatment period compared to olanzapine.

"There is a clear and compelling clinical rationale for developing an antipsychotic with the powerful efficacy of olanzapine while addressing the significant weight gain associated with its use," said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes, "The completion of enrollment of this carefully conducted, multinational study represents an important milestone in the development program for ALKS 3831, as it moves us one step closer to providing this potential, important new treatment option to patients suffering from schizophrenia."

The ENLIGHTEN program also includes supportive studies to evaluate the pharmacokinetic and metabolic profile of ALKS 3831, as well as long-term safety. The clinical data from the ENLIGHTEN-1 and ENLIGHTEN-2 studies, will become the base of the New Drug Application (NDA) to be submitted to the US Food and Drug Administration for ALKS 3831 for the treatment of schizophrenia.

About Schizophrenia

Schizophrenia is a chronic, severe, and disabling brain disorder. The disease is marked by positive symptoms (hallucinations and delusions) and negative symptoms (depression, blunted emotions and social withdrawal), as well as by disorganized thinking. An estimated 2.4 million American adults have schizophrenia, with men and women affected equally.

Stock Performance

At the close of trading session on Monday, May 01, 2017, following the announcement, Alkermes' stock price rose 1.87% to end the day at $59.34. A total volume of 1.02 million shares were exchanged during the session, which was above the 3-month average volume of 874.13 thousand shares. The Company's share price has gained 49.28% in the past twelve months and 6.77% on a YTD basis. The stock currently has a market cap of $9.06 billion.

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@activewallst.com

Phone number: 1-858-257-3144

Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active Wall Street